Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Completed · Phase 4

Conditions studied: Glaucoma, Ocular Hypertension

In brief

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%

Key facts

Study ID

NCT00440011

Run by

Allergan

People needed

266

Starts

2006-08-01

Expected to finish

2007-10-01

Last updated by the study team

2019-04-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Glaucoma or ocular hypertension in both eyes
• Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering
• Best-corrected visual acuity of 20/100 or better in each eye
• Visual field within 6 months of study entry

You may not qualify if…

• Secondary glaucoma
• Active intraocular inflammation or macular edema
• Intraocular surgery or laser surgery within the past 3 months

Where it is running

• Study site — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.